Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/25010
DC FieldValueLanguage
dc.contributor.authorVeljanoska, Slavicaen_US
dc.contributor.authorKlisarovska, Violetaen_US
dc.contributor.authorArsovski, Oliveren_US
dc.contributor.authorBasheska, Nelien_US
dc.contributor.authorStojkovski, Igoren_US
dc.contributor.authorSimonova, Danielaen_US
dc.date.accessioned2022-12-19T13:03:25Z-
dc.date.available2022-12-19T13:03:25Z-
dc.date.issued2011-09-
dc.identifier.urihttp://hdl.handle.net/20.500.12188/25010-
dc.description.abstractBackground: The aim of the study was to evaluate the value of Capecitabine (Xelode) in treatment of epithelial ovarian cancer, after failure of initial chemotherapy. Response rates to first-line chemotherapy in women with ovarian cancer are high but most patients relapse and need further treatment. Recurrent disease is incurable, however, many patients can obtain good palliation from further treatment. Material and Method: The study included 20 patients with epithelial ovarian cancer treated initially with cytoreductive surgery and followed by chemotherapy treatment: 14 patients received platinum/paclitaxel therapy and 6 patients received platinum/cyclophosphamide therapy. Progression of disease was manifested with hepatic metastases in 11 patients (55%), lung metastases in 2 (10%) and an increase in serum CA125 in 5 patients (25%). Comparison of the value of serum CA125 before and after treatment was taken as an indicator of response to chemotherapy. The treatment schedule consisted of oral capecitabine 1250mg/m2 administrated twice daily for 14 days, followed by 7-day rest period. Treatment was administrated orally within 30 min of breakfast and dinner, and swallowed with approximately 200ml of water. The cycle was repeated every 21 days. Results: 18 patients (80%) received 6 courses chemotherapy with Capecitabine, 4 (20%) did not achieve the planned 6 courses of chemotherapy due to deterioration of their general condition. In 10 patients (50%) deceased value of CA125 was observed, in 8 (40%) value was unchanged, and in 2 (10%) an increase of serum CA125 was noted. All 20 patients were evaluable for safety. Capecitabine was very well tolerated, with the most common clinical adverse events being nausea and diarrhoea, neither of which occurred with grade 3 or 4 intensity. Conclusions: Capecitabine has demonstrated promising activity and a favorable safety profile in the treatment of platinum-refractory epithelial ovarian cancer. The safety and convenience advantages afforded to patients over current i.v. options make capecitabine an ideal agent for administration in the outpatient setting, potentially freeing them from the burden of i.v. therapy.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofEuropean Journal of Canceren_US
dc.subjectovaryen_US
dc.subjectepithelial canceren_US
dc.subjectrecurrenceen_US
dc.subjectchemotherapyen_US
dc.subjectcapecitabine chemotherapyen_US
dc.titleCapecitabine as Second and Third-line Chemotherapy in the Treatment of Platinum-refractory Epithelial Ovarian Canceren_US
dc.typeProceeding articleen_US
dc.relation.conferenceThe European Multidisciplinary Cancer Congress, 23-27 September, 2011, Stockholm, Swedenen_US
dc.identifier.doi10.1016/S0959-8049(11)72122-0-
item.fulltextWith Fulltext-
item.grantfulltextopen-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
Appears in Collections:Faculty of Medicine: Conference papers
Files in This Item:
File Description SizeFormat 
EJC 2011 abstact.pdf718.59 kBAdobe PDFView/Open
EJC 2011 cover.pdf944.25 kBAdobe PDFView/Open
Show simple item record

Page view(s)

81
checked on Aug 8, 2024

Download(s)

21
checked on Aug 8, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.